G Rasi

Author PubWeight™ 21.97‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Who benefits from immunotherapy? Allergy 1997 1.97
2 From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 2015 1.59
3 The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp Cell Res 2009 1.27
4 Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008 0.97
5 Nerve growth factor: neurotrophin or cytokine? Int Arch Allergy Immunol 2003 0.96
6 Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol 2000 0.95
7 Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol 2010 0.92
8 Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts. Biomed Microdevices 1999 0.89
9 Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Res 1996 0.85
10 High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 1998 0.84
11 Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy 2006 0.84
12 Nerve growth factor and asthma. Allergy 2002 0.83
13 Nonspecific provocation of target organs in allergic diseases: EAACI-GA(2)LEN consensus report. Allergy 2007 0.81
14 Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. Allergy 2007 0.80
15 A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP)--a possible new tumor marker. Anticancer Res 1996 0.79
16 Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 1995 0.79
17 What we should learn from the London Olympics. Curr Opin Allergy Clin Immunol 2013 0.79
18 The heterogeneity of allergic phenotypes: genetic and environmental interactions. Ann Allergy Asthma Immunol 2001 0.79
19 Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering? Anticancer Res 1999 0.77
20 Combination therapy with BRMs in cancer and infectious diseases. Mech Ageing Dev 1997 0.77
21 Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. Allergy 2004 0.77
22 Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. Histochem J 1999 0.77
23 Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis. Anticancer Res 2000 0.76
24 Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 1992 0.76
25 Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis. Am J Pathol 1999 0.75
26 [Beta-glucronidase activity of granulocytes in patients with rheumatoid arthritis]. Boll Soc Ital Biol Sper 1975 0.75
27 Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother 1999 0.75
28 Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Curr Probl Dermatol 1999 0.75
29 Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. Ann Oncol 1995 0.75
30 Effectiveness of a new device to retain carcinogenic compounds of tar from mainstream cigarette smoke for the prevention of smoking-associated tumors. Anticancer Res 2001 0.75
31 Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms. Anticancer Res 1998 0.75
32 IgE in leprosy. Int J Lepr Other Mycobact Dis 1982 0.75
33 IgE serum levels in urinary schistosomiasis. Tropenmed Parasitol 1979 0.75